STXS Quote, Financials, Valuation and Earnings

Cutera has a net margin of -67.31% compared to Stereotaxis's net margin of -120.06%. Stereotaxis's return on equity of -108.68% beat Cutera's return on equity of --.

Stereotaxis has a consensus price target of --, signalling upside risk potential of 96.51%. On the other hand Cutera has an analysts' consensus of -- which suggests that it could grow by 509.76%. Given that Cutera has higher upside potential than Stereotaxis, analysts believe Cutera is more attractive than Stereotaxis.

Stereotaxis has a beta of 1.570, which suggesting that the stock is 57.046% more volatile than S&P 500. In comparison Cutera has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.313%.

Stereotaxis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cutera offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis pays -- of its earnings as a dividend. Cutera pays out -- of its earnings as a dividend.

Stereotaxis quarterly revenues are $9.2M, which are smaller than Cutera quarterly revenues of $32.5M. Stereotaxis's net income of -$6.2M is higher than Cutera's net income of -$39M. Notably, Stereotaxis's price-to-earnings ratio is -- while Cutera's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis is 7.66x versus 0.04x for Cutera. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -67.31% compared to Stereotaxis's net margin of 10.05%. Stereotaxis's return on equity of -108.68% beat Electromed's return on equity of 15.62%.

Stereotaxis has a consensus price target of --, signalling upside risk potential of 96.51%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 12.86%. Given that Stereotaxis has higher upside potential than Electromed, analysts believe Stereotaxis is more attractive than Electromed.

Stereotaxis has a beta of 1.570, which suggesting that the stock is 57.046% more volatile than S&P 500. In comparison Electromed has a beta of 0.285, suggesting its less volatile than the S&P 500 by 71.506%.

Stereotaxis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Stereotaxis quarterly revenues are $9.2M, which are smaller than Electromed quarterly revenues of $14.7M. Stereotaxis's net income of -$6.2M is lower than Electromed's net income of $1.5M. Notably, Stereotaxis's price-to-earnings ratio is -- while Electromed's PE ratio is 40.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis is 7.66x versus 4.57x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX has a net margin of -67.31% compared to Stereotaxis's net margin of -16.69%. Stereotaxis's return on equity of -108.68% beat IRIDEX's return on equity of -157.91%.

Stereotaxis has a consensus price target of --, signalling upside risk potential of 96.51%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 19.76%. Given that Stereotaxis has higher upside potential than IRIDEX, analysts believe Stereotaxis is more attractive than IRIDEX.

Stereotaxis has a beta of 1.570, which suggesting that the stock is 57.046% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.812, suggesting its less volatile than the S&P 500 by 18.837%.

Stereotaxis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

Stereotaxis quarterly revenues are $9.2M, which are smaller than IRIDEX quarterly revenues of $11.6M. Stereotaxis's net income of -$6.2M is lower than IRIDEX's net income of -$1.9M. Notably, Stereotaxis's price-to-earnings ratio is -- while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis is 7.66x versus 0.56x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -67.31% compared to Stereotaxis's net margin of -10.5%. Stereotaxis's return on equity of -108.68% beat Myomo's return on equity of -84.04%.

Stereotaxis has a consensus price target of --, signalling upside risk potential of 96.51%. On the other hand Myomo has an analysts' consensus of $7.04 which suggests that it could grow by 20.36%. Given that Stereotaxis has higher upside potential than Myomo, analysts believe Stereotaxis is more attractive than Myomo.

Stereotaxis has a beta of 1.570, which suggesting that the stock is 57.046% more volatile than S&P 500. In comparison Myomo has a beta of 1.709, suggesting its more volatile than the S&P 500 by 70.858%.

Stereotaxis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Stereotaxis quarterly revenues are $9.2M, which are smaller than Myomo quarterly revenues of $9.2M. Stereotaxis's net income of -$6.2M is lower than Myomo's net income of -$966.4K. Notably, Stereotaxis's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis is 7.66x versus 9.30x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.